Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

Zonneville et al. show that p53 mutant cancers express high levels of the Base Excision Repair (BER) pathway and that deoxyuridine analogues induce DNA damage in p53-mutant TNBC cells. They exploit this genetic liability for therapeutic purposes using a combination of fluorinated deoxyuridine analog...

Full description

Bibliographic Details
Main Authors: Justin Zonneville, Moyi Wang, Mohammed M. Alruwaili, Brandon Smith, Megan Melnick, Kevin H. Eng, Thomas Melendy, Ben Ho Park, Renuka Iyer, Christos Fountzilas, Andrei V. Bakin
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-021-02370-0

Internet

https://doi.org/10.1038/s42003-021-02370-0

Similar Items